Short answer
Aclaris Therapeutics, Inc. (ACRS) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 2025 earnings press release filed as exhibit: refer to Exhibit 99.1 for actual financial results.
Aclaris Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2025 earnings press release filed as exhibit: refer to Exhibit 99.1 for actual financial results
- Filing explicitly excludes Item 2.02 disclosure from liability under Exchange Act Section 18
- Non-incorporation clause means results won't automatically flow into future SEC filings unless specifically referenced
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aclaris Therapeutics, Inc. 8-K filings
Get the next ACRS 8-K as it lands
Follow ACRS for push alerts, or ask the research agent what this filing means.